The board of directors of Grand Pharmaceutical Group Limited announced the following changes to the Board: RESIGNATION OF EXECUTIVE DIRECTOR:
Dr. Shi Lin ("Dr. Shi") has resigned as an executive director of the Company with effect from 24 June 2024 due to her desire to devote more time to her personal endeavours. Dr. Xing Li Na ("Dr. Xing") has been appointed as an non-executive director of the Company with effect from 24 June 2024. Dr. Xing, aged 40, joined China Grand Enterprises, INC. in November 2023 as senior business director of the pharmaceutical strategic management headquarters. She has many years of experience in review work at the Medical Device Technical Review Center of the State Food and Drug Administration, and served as deputy director of preclinical safety research for new drugs at BeiGene (Beijing) Biotechnology Co. Ltd. Dr. Xing obtained a
post graduate degree in medicine from Peking University School of Medicine in 2012.